Leo Lens Pharma Changes Name to MediPrint Ophthalmics, and Closes Seed Round Fundraising

SAN DIEGO—Leo Lens Pharma, an emerging San Diego-based clinical stage eyecare pharmaceutical company focused on helping protect sight, announced that it is changing its name to MediPrint Ophthalmics, effective immediately. The company also reported that it has successfully closed an over-subscribed seed round fundraising. The company changed its name as it prepares for the first clinical trials of its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hypertension.

“This is an especially exciting time for MediPrint Ophthalmics as we start a new stage in our journey to help protect sight for patients suffering from potentially debilitating eye diseases such as glaucoma,” commented Dan Myers, CEO of MediPrint Ophthalmics. “Our new corporate identity will make it easier for patients and eyecare professionals to identify us and understand what we aim to do. And closing our Seed round successfully is a tribute to the hard work our team has done to date and to the vision for the future of eyecare we gratefully share with a group of passionate investors,” he added.

Another significant milestone for the company is the close of an over-subscribed seed round fundraising. The total raised in the seed round exceeded $4.0 million, with $2.6 million from new investors, including from the lead investor which is the venture arm of a leading global ophthalmic pharmaceutical company. As previously reported, these funds are intended primarily to support the Phase 2a clinical study along with the end of Phase 2 meeting with the FDA, MediPrint Ophthalmics said.